Targeting chronic inflammation as a potential adjuvant therapy for osteoporosis

Gregory Livshits*, Alexander Kalinkovich

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Systemic, chronic, low-grade inflammation (SCLGI) underlies the pathogenesis of various widespread diseases. It is often associated with bone loss, thus connecting chronic inflammation to the pathogenesis of osteoporosis. In postmenopausal women, osteoporosis is accompanied by SCLGI development, likely owing to estrogen deficiency. We propose that SCGLI persistence in osteoporosis results from failed inflammation resolution, which is mainly mediated by specialized, pro-resolving mediators (SPMs). In corroboration, SPMs demonstrate encouraging therapeutic effects in various preclinical models of inflammatory disorders, including bone pathology. Since numerous data implicate gut dysbiosis in osteoporosis-associated chronic inflammation, restoring balanced microbiota by supplementing probiotics and prebiotics could contribute to the efficient resolution of SCGLI. In the present review, we provide evidence for this hypothesis and argue that efficient SCGLI resolution may serve as a novel approach for treating osteoporosis, complementary to traditional anti-osteoporotic medications.

Original languageEnglish
Article number120847
JournalLife Sciences
StatePublished - 1 Oct 2022


FundersFunder number
Ariel University Research & Development DepartmentRA2000000457
Israel Science Foundation2054/19


    • Chronic inflammation
    • Gut dysbiosis
    • Osteoporosis
    • Specialized pro-resolving mediators


    Dive into the research topics of 'Targeting chronic inflammation as a potential adjuvant therapy for osteoporosis'. Together they form a unique fingerprint.

    Cite this